{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:18:25Z","timestamp":1777544305291,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1476-511x-13-41","type":"journal-article","created":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T04:13:14Z","timestamp":1393647194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement"],"prefix":"10.1186","volume":"13","author":[{"given":"Dongdan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FanFang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huocheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruofeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rulin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyi","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"1048_CR1","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.109.849166","volume":"121","author":"DM Lloyd-Jones","year":"2010","unstructured":"Lloyd-Jones DM: Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation. 2010, 121: 1768-1777. 10.1161\/CIRCULATIONAHA.109.849166","journal-title":"Circulation"},{"key":"1048_CR2","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","volume":"123","author":"PA Heidenreich","year":"2011","unstructured":"Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ: Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011, 123: 933-944. 10.1161\/CIR.0b013e31820a55f5","journal-title":"Circulation"},{"key":"1048_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R: Atherosclerosis\u2013an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056\/NEJM199901143400207","journal-title":"N Engl J Med"},{"key":"1048_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bmb\/ldr043","volume":"100","author":"M Madjid","year":"2011","unstructured":"Madjid M, Willerson JT: Inflammatory markers in coronary heart disease. Br Med Bull. 2011, 100: 23-38. 10.1093\/bmb\/ldr043","journal-title":"Br Med Bull"},{"key":"1048_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/157488711795177903","volume":"6","author":"I Ikonomidis","year":"2011","unstructured":"Ikonomidis I, Michalakeas CA, Lekakis J, Parissis J, Anastasiou-Nana M: The role of lipoprotein-associated phospholipase A2 (Lp-PLA(2)) in cardiovascular disease. Rev Recent Clin Trials. 2011, 6: 108-113. 10.2174\/157488711795177903","journal-title":"Rev Recent Clin Trials"},{"key":"1048_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1155\/2013\/432136","volume":"34","author":"A Cai","year":"2013","unstructured":"Cai A, Zheng D, Qiu R, Mai W, Zhou Y: Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers. 2013, 34: 323-331. 10.1155\/2013\/432136","journal-title":"Dis Markers"},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1096\/fj.99-1029com","volume":"14","author":"G Theilmeier","year":"2000","unstructured":"Theilmeier G, De Geest B, Van Veldhoven PP, Stengel D, Michiels C, Lox M, Landeloos M, Chapman MJ, Ninio E, Collen D, Himpens B, Holvoet P: HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-\/-mice. FASEB J. 2000, 14: 2032-2039. 10.1096\/fj.99-1029com","journal-title":"FASEB J"},{"key":"1048_CR8","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/nm.1870","volume":"14","author":"RL Wilensky","year":"2008","unstructured":"Wilensky RL, Shi Y, Mohler ER, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH: Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008, 14: 1059-1066. 10.1038\/nm.1870","journal-title":"Nat Med"},{"key":"1048_CR9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ahj.2006.01.011","volume":"152","author":"HT May","year":"2006","unstructured":"May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, Clarke JL, Kolek MJ, Bair TL, Pearson RR, Sudhir K, Carlquist JF: Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J. 2006, 152: 997-1003. 10.1016\/j.ahj.2006.01.011","journal-title":"Am Heart J"},{"key":"1048_CR10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.atherosclerosis.2009.09.021","volume":"209","author":"NS Jenny","year":"2010","unstructured":"Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, Furberg CD: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis. 2010, 209: 528-532. 10.1016\/j.atherosclerosis.2009.09.021","journal-title":"Atherosclerosis"},{"key":"1048_CR11","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","volume":"375","author":"A Thompson","year":"2010","unstructured":"Thompson A, Gao P, Orfei L, Watson S, Di AE, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J: Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010, 375: 1536-1544.","journal-title":"Lancet"},{"key":"1048_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.atherosclerosis.2011.09.019","volume":"219","author":"T Dohi","year":"2011","unstructured":"Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Ohkawa R, Nakamura K, Yanagisawa N, Tsuboi S, Ogita M, Yokoyama K, Kurata T, Yatomi Y, Daida H: Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. Atherosclerosis. 2011, 219: 907-912. 10.1016\/j.atherosclerosis.2011.09.019","journal-title":"Atherosclerosis"},{"key":"1048_CR13","doi-asserted-by":"publisher","first-page":"23F","DOI":"10.1016\/j.amjcard.2008.04.015","volume":"101","author":"JL Anderson","year":"2008","unstructured":"Anderson JL: Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008, 101: 23F-33F. 10.1016\/j.amjcard.2008.04.015","journal-title":"Am J Cardiol"},{"key":"1048_CR14","doi-asserted-by":"publisher","first-page":"41F","DOI":"10.1016\/j.amjcard.2008.04.018","volume":"101","author":"MA Corson","year":"2008","unstructured":"Corson MA, Jones PH, Davidson MH: Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008, 101: 41F-50F. 10.1016\/j.amjcard.2008.04.018","journal-title":"Am J Cardiol"},{"key":"1048_CR15","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350: 1495-1504. 10.1056\/NEJMoa040583","journal-title":"N Engl J Med"},{"key":"1048_CR16","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005, 294: 2437-2445. 10.1001\/jama.294.19.2437","journal-title":"JAMA"},{"key":"1048_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","volume":"117","author":"PR Kamstrup","year":"2008","unstructured":"Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG: Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008, 117: 176-184. 10.1161\/CIRCULATIONAHA.107.715698","journal-title":"Circulation"},{"key":"1048_CR18","doi-asserted-by":"publisher","first-page":"51F","DOI":"10.1016\/j.amjcard.2008.04.019","volume":"101","author":"MH Davidson","year":"2008","unstructured":"Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, Lerman A, McConnell JP, Weintraub HS: Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008, 101: 51F-57F. 10.1016\/j.amjcard.2008.04.019","journal-title":"Am J Cardiol"},{"key":"1048_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/eurheartj\/ehi010","volume":"26","author":"ES Brilakis","year":"2005","unstructured":"Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005, 26: 137-144.","journal-title":"Eur Heart J"},{"key":"1048_CR20","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","volume":"27","author":"S Kiechl","year":"2007","unstructured":"Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S: Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007, 27: 1788-1795. 10.1161\/ATVBAHA.107.145805","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1048_CR21","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/eurheartj\/ehp122","volume":"30","author":"A Tanaka","year":"2009","unstructured":"Tanaka A, Imanishi T, Kitabata H, Kubo T, Takarada S, Tanimoto T, Kuroi A, Tsujioka H, Ikejima H, Komukai K, Kataiwa H, Okouchi K, Kashiwaghi M, Ishibashi K, Matsumoto H, Takemoto K, Nakamura N, Hirata K, Mizukoshi M, Akasaka T: Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. Eur Heart J. 2009, 30: 1348-1355. 10.1093\/eurheartj\/ehp122","journal-title":"Eur Heart J"},{"key":"1048_CR22","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","volume":"304","author":"JL Mega","year":"2010","unstructured":"Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS: Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010, 304: 1821-1830. 10.1001\/jama.2010.1543","journal-title":"JAMA"},{"key":"1048_CR23","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.jacc.2009.11.063","volume":"55","author":"P Sorajja","year":"2010","unstructured":"Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, Stone GW: Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2010, 55: 1416-1424. 10.1016\/j.jacc.2009.11.063","journal-title":"J Am Coll Cardiol"},{"key":"1048_CR24","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005, 352: 1425-1435. 10.1056\/NEJMoa050461","journal-title":"N Engl J Med"},{"key":"1048_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2012.03.021","volume":"222","author":"DM Breen","year":"2012","unstructured":"Breen DM, Dolinsky VW, Zhang H, Ghanim H, Guo J, Mroziewicz M, Tsiani EL, Bendeck MP, Dandona P, Dyck JR, Heximer SP, Giacca A: Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Atherosclerosis. 2012, 222: 375-381. 10.1016\/j.atherosclerosis.2012.03.021","journal-title":"Atherosclerosis"},{"key":"1048_CR26","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.jacc.2011.10.909","volume":"59","author":"SJ Park","year":"2012","unstructured":"Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y: In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012, 59: 2051-2057. 10.1016\/j.jacc.2011.10.909","journal-title":"J Am Coll Cardiol"},{"key":"1048_CR27","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/HCO.0b013e32832bcb22","volume":"24","author":"CJ Packard","year":"2009","unstructured":"Packard CJ: Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Curr Opin Cardiol. 2009, 24: 358-363. 10.1097\/HCO.0b013e32832bcb22","journal-title":"Curr Opin Cardiol"},{"key":"1048_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MOL.0b013e32833eb581","volume":"21","author":"RS Rosenson","year":"2010","unstructured":"Rosenson RS: Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. Curr Opin Lipidol. 2010, 21: 473-480. 10.1097\/MOL.0b013e32833eb581","journal-title":"Curr Opin Lipidol"},{"key":"1048_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13167-011-0063-4","volume":"2","author":"KJ Colley","year":"2011","unstructured":"Colley KJ, Wolfert RL, Cobble ME: Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. 2011, 2: 27-38. 10.1007\/s13167-011-0063-4","journal-title":"EPMA J"},{"key":"1048_CR30","doi-asserted-by":"crossref","unstructured":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002, 106: 3143-3421.","DOI":"10.1161\/circ.106.25.3143"},{"key":"1048_CR31","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.clinbiochem.2008.09.109","volume":"41","author":"E Moldoveanu","year":"2008","unstructured":"Moldoveanu E, Mut-Vitcu B, Tanaseanu GR, Marta DS, Manea G, Kosaka T, Vidulescu C, Tanaseanu C: Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase. Clin Biochem. 2008, 41: 1429-1433. 10.1016\/j.clinbiochem.2008.09.109","journal-title":"Clin Biochem"},{"key":"1048_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.clinbiochem.2003.12.007","volume":"37","author":"MB Boffa","year":"2004","unstructured":"Boffa MB, Marcovina SM, Koschinsky ML: Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004, 37: 333-343. 10.1016\/j.clinbiochem.2003.12.007","journal-title":"Clin Biochem"},{"key":"1048_CR33","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1161\/01.ATV.0000280571.28102.d4","volume":"27","author":"S Tsimikas","year":"2007","unstructured":"Tsimikas S, Tsironis LD, Tselepis AD: New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2007, 27: 2094-2099. 10.1161\/01.ATV.0000280571.28102.d4","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1048_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1358863X11411360","volume":"16","author":"PK Garg","year":"2011","unstructured":"Garg PK, McClelland RL, Jenny NS, Criqui M, Liu K, Polak JF, Jorgensen NW, Cushman M: Association of lipoprotein-associated phospholipase A(2) and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Vasc Med. 2011, 16: 247-252. 10.1177\/1358863X11411360","journal-title":"Vasc Med"},{"key":"1048_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2004.10.025","volume":"179","author":"P Turunen","year":"2005","unstructured":"Turunen P, Puhakka H, Rutanen J, Hiltunen MO, Heikura T, Gruchala M, Yla-Herttuala S: Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Atherosclerosis. 2005, 179: 27-33. 10.1016\/j.atherosclerosis.2004.10.025","journal-title":"Atherosclerosis"},{"key":"1048_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11897-013-0131-2","volume":"10","author":"P Detopoulou","year":"2013","unstructured":"Detopoulou P, Nomikos T, Fragopoulou E, Chrysohoou C, Antonopoulou S: Platelet Activating Factor in Heart Failure: Potential Role in Disease Progression and Novel Target for Therapy. Curr Heart Fail Rep. 2013, 10: 122-129. 10.1007\/s11897-013-0131-2","journal-title":"Curr Heart Fail Rep"},{"key":"1048_CR37","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJM200010193431603","volume":"343","author":"CJ Packard","year":"2000","unstructured":"Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000, 343: 1148-1155. 10.1056\/NEJM200010193431603","journal-title":"N Engl J Med"},{"key":"1048_CR38","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1194\/jlr.M300086-JLR200","volume":"44","author":"S Blankenberg","year":"2003","unstructured":"Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, Tiret L, Ninio E: Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res. 2003, 44: 1381-1386. 10.1194\/jlr.M300086-JLR200","journal-title":"J Lipid Res"},{"key":"1048_CR39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0025-6196(11)60992-0","volume":"82","author":"CA Garza","year":"2007","unstructured":"Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F: Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007, 82: 159-165. 10.1016\/S0025-6196(11)60992-0","journal-title":"Mayo Clin Proc"},{"key":"1048_CR40","first-page":"RA5","volume":"12","author":"P Kougias","year":"2006","unstructured":"Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C: Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit. 2006, 12: RA5-RA16.","journal-title":"Med Sci Monit"},{"key":"1048_CR41","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/01.CIR.0000158482.83179.DB","volume":"111","author":"R Takeda","year":"2005","unstructured":"Takeda R, Suzuki E, Satonaka H, Oba S, Nishimatsu H, Omata M, Fujita T, Nagai R, Hirata Y: Blockade of endogenous cytokines mitigates neointimal formation in obese Zucker rats. Circulation. 2005, 111: 1398-1406. 10.1161\/01.CIR.0000158482.83179.DB","journal-title":"Circulation"},{"key":"1048_CR42","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1476-5381.2011.01404.x","volume":"165","author":"CY Miao","year":"2012","unstructured":"Miao CY, Li ZY: The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol. 2012, 165: 643-658. 10.1111\/j.1476-5381.2011.01404.x","journal-title":"Br J Pharmacol"},{"key":"1048_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1476-511X-8-19","volume":"8","author":"P Detopoulou","year":"2009","unstructured":"Detopoulou P, Nomikos T, Fragopoulou E, Panagiotakos DB, Pitsavos C, Stefanadis C, Antonopoulou S: Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults. Lipids Health Dis. 2009, 8: 19- 10.1186\/1476-511X-8-19","journal-title":"Lipids Health Dis"},{"key":"1048_CR44","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.ehj.2004.04.027","volume":"25","author":"A Segev","year":"2004","unstructured":"Segev A, Kassam S, Buller CE, Lau HK, Sparkes JD, Connelly PW, Seidelin PH, Natarajan MK, Cohen EA, Strauss BH: Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J. 2004, 25: 1029-1035. 10.1016\/j.ehj.2004.04.027","journal-title":"Eur Heart J"},{"key":"1048_CR45","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.carrev.2009.01.005","volume":"10","author":"C Delhaye","year":"2009","unstructured":"Delhaye C, Sudre A, Lemesle G, Marechaux S, Broucqsault D, Hennache B, Bauters C, Lablanche JM: Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. Cardiovasc Revasc Med. 2009, 10: 144-150.","journal-title":"Cardiovasc Revasc Med"},{"key":"1048_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.atherosclerosissup.2005.02.005","volume":"6","author":"CM Ballantyne","year":"2005","unstructured":"Ballantyne CM, Nambi V: Markers of inflammation and their clinical significance. Atheroscler Suppl. 2005, 6: 21-29.","journal-title":"Atheroscler Suppl"},{"key":"1048_CR47","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/archinte.166.19.2073","volume":"166","author":"MS Elkind","year":"2006","unstructured":"Elkind MS, Tai W, Coates K, Paik MC, Sacco RL: High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006, 166: 2073-2080. 10.1001\/archinte.166.19.2073","journal-title":"Arch Intern Med"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-511X-13-41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T19:19:27Z","timestamp":1630610367000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/1476-511X-13-41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1186\/1476-511x-13-41","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,1]]},"assertion":[{"value":"7 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"41"}}